Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis

[1]  X. Montalban,et al.  Ocrelizumab: a new milestone in multiple sclerosis therapy , 2018, Therapeutic advances in neurological disorders.

[2]  O. Kovalchuk,et al.  Global transcriptome profiling of mild relapsing‐remitting versus primary progressive multiple sclerosis , 2018, European journal of neurology.

[3]  R. Bakshi,et al.  Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. , 2017, International journal of MS care.

[4]  Rohit Bakshi,et al.  Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis , 2017, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[5]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[6]  Ludwig Kappos,et al.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[7]  J. Gore,et al.  Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis at 7T , 2016, Multiple sclerosis.

[8]  David H. Miller,et al.  Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value , 2015, Nature Reviews Neurology.

[9]  L. Wilkins,et al.  Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[10]  Tanuja Chitnis,et al.  Progression rates and sample size estimates for PPMS based on the CLIMB study population , 2015, Multiple sclerosis.

[11]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[12]  F. Barkhof,et al.  Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  F. Paul,et al.  Identical lesion morphology in primary progressive and relapsing–remitting MS –an ultrahigh field MRI study , 2014, Multiple sclerosis.

[14]  G. Comi.  Disease-modifying treatments for progressive multiple sclerosis , 2013, Multiple sclerosis.

[15]  Rohit Bakshi,et al.  The Relationships among MRI‐Defined Spinal Cord Involvement, Brain Involvement, and Disability in Multiple Sclerosis , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[16]  Rohit Bakshi,et al.  Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[17]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[18]  V. Honti,et al.  APOE epsilon status in Hungarian patients with primary progressive multiple sclerosis. , 2010, Swiss medical weekly.

[19]  P. Sørensen,et al.  Demyelination versus remyelination in progressive multiple sclerosis. , 2010, Brain : a journal of neurology.

[20]  F. Barkhof,et al.  HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. , 2009, Archives of neurology.

[21]  R Bakshi,et al.  Normal Findings on Brain Fluid-Attenuated Inversion Recovery MR Images at 3T , 2009, American Journal of Neuroradiology.

[22]  D. Alsop,et al.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study , 2009, Journal of the Neurological Sciences.

[23]  F. Barkhof,et al.  Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques. , 2009, Neuroimaging clinics of North America.

[24]  Rohit Bakshi,et al.  Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. , 2008, Archives of neurology.

[25]  J. De Keyser,et al.  Progression in familial and nonfamilial MS , 2008, Multiple sclerosis.

[26]  M. Battaglini,et al.  Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. , 2008, Archives of neurology.

[27]  Anne H. Cross,et al.  DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS , 2007 .

[28]  David H. Miller,et al.  Primary-progressive multiple sclerosis , 2007, The Lancet Neurology.

[29]  P. Narayana,et al.  Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.

[30]  Susan A Gauthier,et al.  A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. , 2006, Autoimmunity reviews.

[31]  A J Thompson,et al.  Is inflammation important in early PPMS? a longitudinal MRI study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  M. Rovaris,et al.  Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. , 2005, AJNR. American journal of neuroradiology.

[33]  R. Bakshi,et al.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. , 2004, AJNR. American journal of neuroradiology.

[34]  C. Lucchinetti,et al.  The pathology of primary progressive multiple sclerosis , 2004, Multiple sclerosis.

[35]  G. Scotti,et al.  Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord , 2000, Neuroradiology.

[36]  M. Horsfield,et al.  A conventional and magnetization transfer MRI study of the cervical cord in patients with MS , 2000, Neurology.

[37]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[38]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[39]  A J Thompson,et al.  PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS , 1997 .

[40]  S. Tobimatsu,et al.  Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients: A combined clinical, magnetic resonance imaging and multimodality evoked potential study , 1993, Journal of the Neurological Sciences.

[41]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[42]  J. Kurtzke.  DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS , 1970, Acta neurologica Scandinavica.

[43]  M. Filippi,et al.  Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.

[44]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.